SCHEMBL5786143

SCHEMBL5786143

O=C(O)c1cccc(-c2cc3cc(F)c(F)cc3o2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 0.50
▸ POLB P06746 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ KMO O15229 1/20 0.46
▸ HDAC6 Q9UBN7 3/20 0.46
▸ MAOA P21397 2/20 0.46
▸ BLVRB P30043 1/20 0.46
▸ PRKDC P78527 1/20 0.43
▸ ERN1 O75460 1/20 0.43
▸ PTPN1 P18031 1/20 0.42
▸ PTGS2 P35354 1/20 0.42
▸ RXRA P19793 1/20 0.42
▸ RXRB P28702 1/20 0.42
▸ NR4A1 P22736 1/20 0.41
▸ NR4A2 P43354 1/20 0.41
▸ NR4A3 Q92570 1/20 0.41
▸ AR P10275 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5787184 0.83 KEAP1 (0.50) KEAP1POLBKDM4EALDH1A1TDP1
SCHEMBL4601674 0.81 MAOB (0.58) KEAP1POLBKDM4EALDH1A1TDP1
SCHEMBL5786569 0.79 RXRA (0.51) KEAP1POLBKDM4EALDH1A1TDP1
SCHEMBL31346192 0.76 MAOB (0.64) MAOAMAOB
SCHEMBL4602054 0.76 MAPT (0.56) KDM4EALDH1A1HDAC6MAOAFFAR1
SCHEMBL977340 0.74 FFAR1 (0.58) HDAC6FFAR1MAOB
SCHEMBL977056 0.74 HDAC6 (0.73) KDM4EALDH1A1KMOHDAC6PTGS2
SCHEMBL13137668 0.72 KMO (0.63) KEAP1KDM4EALDH1A1KMOHDAC6
SCHEMBL28381454 0.71 MAPT (0.51) KDM4EALDH1A1L3MBTL1HDAC6MAOA
SCHEMBL977613 0.70 HDAC3 (0.62) KDM4EALDH1A1HDAC6MAOAFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060205751-A1 Novel compounds SMITHKLINE BEECHAM CORPORATION (US) 2006-09-14 — — US claimed
EP-1648885-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-04-26 — — EP claimed
WO-2005009993-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-02-03 — — WO claimed
US-20060205751-A1 Novel compounds SMITHKLINE BEECHAM CORPORATION (US) 2006-09-14 — — US disclosed
EP-1648885-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-04-26 — — EP disclosed
WO-2005009993-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-02-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205751-A1 Novel compounds KCNN2, KCNN3, KCNN1 KEAP1 1377/4885POLB 4222/4885KDM4E 1841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback